4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue SUPPL. 1, 2013, Pages 19-23

  Kolbe, L ^a   Mann, T ^a   Gerwat, W ^a   Batzer, J ^a   Ahlheit, S ^a   Scherner, C ^a   Wenck, H ^a   Stab F ^a  

^a BEIERSDORF AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 N BUTYLRESORCINOL; 4-N-BUTYLRESORCINOL; ARBUTIN; DEPIGMENTING AGENT; HYDROQUINONE; HYDROQUINONE DERIVATIVE; KOJIC ACID; MELANIN; MONOPHENOL MONOOXYGENASE; PYRONE DERIVATIVE; RESORCINOL DERIVATIVE;

AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; HYPERPIGMENTATION; IN VITRO STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN; TISSUE CULTURE TECHNIQUE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; ARBUTIN; FEMALE; HUMANS; HYDROQUINONES; HYPERPIGMENTATION; MELANINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; PYRONES; RESORCINOLS; SINGLE-BLIND METHOD; SKIN; SKIN LIGHTENING PREPARATIONS; TISSUE CULTURE TECHNIQUES; TREATMENT OUTCOME;

EID: 84879472132     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12051     Document Type: Article

References (28)

1. Stragitos AJ, Katsambas AD. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol 2004; 5: 161-168.
2. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003; 16: 101-110.
3. Rescigno A, Sollai F, Pisu B, Rinaldi A, Sanjust E. Tyrosinase inhibition, general and applied aspects. J Enzyme Inhib Med Chem 2002; 17: 207-218.
4. Kim YJ, Uyama H. Tyrosinase inhibitors from natural and synthetic sources, structure, inhibition mechanism and perspective for the future. Cell Mol Life Sci 2005; 62: 1707-1723.
5. Chang TS. An updated review of tyrosinase inhibitors. Int J Mol Sci 2009; 10: 2440-2475.
6. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006; 19: 550-571.
7. Winder AJ, Harris H. New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. Eur J Biochem 1991; 198: 317-326.
8. Schweikardt T, Olivares C, Solano F, Jaenicke E, García- Borrón JC, Decker H. A three-dimensional model of mammalian tyrosinase active site accounting for loss of function mutations. Pigment Cell Res 2007; 20: 394-401.
9. Espin JC, Varon R, Fenoll LG et al. Kinetic characterization of the substrate specificity and mechanism of mushroom tyrosinase. Eur J Biochem 2000; 267: 1270-1279.
10. Garcia-Molina F, Hiner AN, Fenoll LG et al. Mushroom tyrosinase: catalase activity, inhibition, and suicide inactivation. J Agric Food Chem 2005; 53: 3702-3709.
11. Kim H, Choi HR, Kim DS, Park KC. Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action. Ann Dermatol 2012;24:1-6.
12. Department of Health and Human Services. Food and Drug Administration. Skin Bleaching Drug Products For Over-the-Counter Human Use; Proposed Rule. 71 Federal Register 51146-5115521 (2006) (codified at 21 CFR Part 310).
13. Kang HH, Rho HS, Hwang JS, Oh SG. Depigmenting activity and low cytotoxicity of alkoxy benzoates or alkoxy cinnamte in cultured melanocytes. Chem Pharm Bull (Tokyo) 2003; 51: 1085-1088.
14. Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol 2009;129:2242-2249.
15. Palumbo A, d'Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta 1991; 1073: 85-90.
16. Parvez S, Kang M, Chung HS et al. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res 2006; 20: 921-934.
17. Sugimoto K, Nomura K, Nishimura T, Kiso T, Sugimoto K, Kuriki T. Syntheses of alpha-arbutin-alpha-glycosides and their inhibitory effects on human tyrosinase. J Biosci Bioeng 2005; 99: 272-276.
18. Scientific Committee on Consumer Products (SCCP). Opinion on barbutin. 15 April 2008. URL http://ec.europa.eu/health/archive/ph-risk/committees/04-sccp/ docs/sccp-o-134.pdf (last accessed: 20 September 2012).
19. Shimizu K, Kondo R, Sakai K. Inhibition of tyrosinase by flavonoids, stilbenes and related 4-substituted resorcinols: structure-activity investigations. Planta Med 2000; 66: 11-15.
20. Jeon SH, Kim KH, Koh JU, Kong KH. Inhibitory effects of L-Dopa oxidation of tyrosinase by skin whitening agents. Bull Korean Chem Soc 2005;26:1135-1137
21. Scientific Committee on Consumer Safety (SCCS), Opinion on kojic acid, 26-27 June 2012. URL http://ec.europa.eu/health/scientific-committees/consumer- safety/docs/sccs-o-098.pdf. (last accessed: 20, September 2012).
22. Burnett CL, Bergfeld WF, Belsito DV et al. Final report of the safety assessment of Kojic acid as used in cosmetics. Int J Toxicol 2010;29 (6 Suppl):244S-73.
23. Khatib S, Nerya O, Musa R, Shmuel M, Tamir S, Vaya J. Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety. Bioorg Med Chem 2005; 13: 433-441.
24. Arung ET, Shimizu K, Kondo R. Artocarpus plants as a potential source of skin whitening agents. Nat Prod Commun 2011; 6: 1397-1402.
25. Kim DS, Kim SY, Park SH et al. Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biol Pharm Bull 2005; 28: 2216-2219.
26. Katagiri T, Okubo T, Oyobikawa M et al. Inhibitory action of 4-nbutylresorcinol on Melanogenesis and its skin whitening effect. J Soc Cosmet Chem Jpn 2001; 35: 42-49.
27. Bohnsack K, Koop U, Hiddemann S, Kolbe L, Rippke F. Pigmentation reducing efficacy and tolerability of six new face care formulations containing 4-n-butylresorcinol, Poster No. P864, 21st EADV Congress, Prague, Czech Republic
28. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. The efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. Ann Dermatol 2010;22:21-25.